VANCOUVER, British Columbia & DALLAS, April 21 — Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations.
“On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader,” said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. “Her broad experience across strategic, financial, and operational roles will be instrumental as we advance the commercial launch of ZUNVEYL and continue development of our sublingual program. We look forward to benefiting from her insight and leadership.”
Ms. Sensenig most recently served as Chief Financial Officer and Head of Operations at Radius Health, Inc., a commercial-stage biopharmaceutical company, where she played a key role in driving growth and financial performance. Previously, she served as Chief Financial Officer, and Interim Chief Executive Officer of 9 Meters Biopharma, a clinical-stage biotechnology company. Prior to that, she was Chief Financial Officer and Head of U.S. Operations at Minovia Therapeutics, Ltd., where she led business and financing strategy.
Earlier in her career, Ms. Sensenig spent 13 years at Biogen Inc., holding roles of increasing responsibility, most recently as Vice President of Finance and Commercial Operations. During her tenure, she held direct P&L responsibility for more than $1 billion in annual revenue across 30 countries spanning the U.S., Asia-Pacific, Latin America, and Europe. She has played key roles in numerous financings, transactions, and acquisitions throughout her career. Ms. Sensenig currently serves on the Board of Directors of Supernus Pharmaceuticals (NASDAQ: SUPN) and KalVista Pharmaceuticals (NASDAQ: KALV).
Alpha Cognition also announced that Len Mertz has informed the Company that he will not seek re-election to the Board of Directors. Mr. Mertz is a founding member of the Board and previously served as Chairman, Chair of the Audit Committee, and a member of the Governance Committee. During his tenure, he provided valuable leadership and guidance, helping to advance the Company to the public markets and progress its pipeline to an FDA-approved product.
The Board of Directors and management team thank Mr. Mertz for his significant contributions to Alpha Cognition and wish him continued success in his future endeavors.
